14 active not recruiting, 5 completed, 3 recruiting, 3 unknown. 16 Phase 1, 12 Phase 2, 2 Early Phase 1, 1 Not applicable.
Follow Recurrent Malignant Glioma: new trials by email Literature Review of Recurrent Malignant Glioma trials Research Report on Recurrent Malignant Glioma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| FPS-ZM1 With or Without Dexamethasone for Controlling Post Operative Cerebral Edema in Patients With Glioblastoma Biospecimen Collection, Computed Tomography, Dexamethasone - Glioblastoma, Malignant Glioma | Phase 1 | Not yet recruiting | City of Hope Medical Center | 24 | 2027-02-17 | 2026-08-27 |
| IL13Rα2 CAR-T Cells Secreting Anti-PD-L1 Antibody for Recurrent Malignant Glioma IL13Rα2 CAR-T Cells Secreting Anti-PD-L1 Antibody - Recurrent Malignant Glioma | Phase 1 | Not yet recruiting | Ming Yang | 24 | 2026-05-01 | 2026-03-19 |
| Comprehensive Analysis of Chemotherapy and Targeted Therapy Outcomes in Recurrent Malignant Gliomas Bevacizumab-Containing Regimens, Non-Bevacizumab Regimens, BRAF ± MEK Targeted Therapy - Recurrent Malignant Glioma, Glioblastoma | Active not recruiting | Blokhin's Russian Cancer Research Center | 1000 | 2026-02-01 | 2026-03-04 | |
| Anti-GARP Chimeric Antigen Receptor T Cell Therapy for the Treatment of Recurrent Grade III or IV Gliomas Anti-GARP Chimeric Antigen Receptor-T Cells, Biospecimen Collection, Chest Radiography - Recurrent Malignant Glioma, Recurrent WHO Grade 3 Glioma | Phase 1 | Recruiting | Ohio State University Comprehensive Cancer Center | 30 | 2025-05-21 | 2026-05-08 |
| Re-Administration of C134 in Patients With Recurrent GBM (C134-HSV-1) C134 Re-Administration - Recurrent Malignant Glioma, Glioblastoma Multiforme of Brain | Phase 1 | Terminated | University of Alabama at Birmingham | 1 | 2024-06-21 | 2026-01-22 |
| Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors LUTATHERA® (Lutetium Lu 177 dotatate) - High Grade Glioma, Meningioma | Phase 1 / Phase 2 | Recruiting | Nationwide Children's Hospital | 65 | 2022-11-21 | 2026-07-20 |
| A Clinical Study of IL13Rα2 Targeted CAR-T in Patients With Malignant Glioma (MAGIC-I) YYB-103 - Recurrent Malignant Glioma | Phase 1 | Unknown | CellabMED | 18 | 2022-07-18 | 2023-01-06 |
| Simultaneous Multinuclear Metabolic MRI in Newly Diagnosed or Recurrent Glioma Biospecimen Collection, Diagnostic Imaging, Magnetic Resonance Imaging - Glioma, Malignant Glioma | Early Phase 1 | Active not recruiting | Jonsson Comprehensive Cancer Center | 36 | 2021-09-01 | 2026-10-20 |
| Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography - Hematopoietic and Lymphatic System Neoplasm, Recurrent Ependymoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 1 | 2021-05-03 | 2026-10-09 |
| Chemotherapy and Donor Stem Transplant for the Treatment of Patients With High Grade Brain Cancer Etoposide, Fludarabine Phosphate, Hematopoietic Cell Transplantation - Anaplastic Ependymoma, Atypical Teratoid/Rhabdoid Tumor | Phase 1 | Withdrawn | M.D. Anderson Cancer Center | 2021-01-14 | 2024-10-26 | |
| Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial Tipifarnib - Malignant Solid Neoplasm, Recurrent Adrenal Gland Pheochromocytoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 5 | 2020-10-13 | 2026-10-16 |
| Immunotherapy Before and After Surgery for Treatment of Recurrent or Progressive High Grade Glioma in Children and Young Adults Nivolumab, Quality-of-Life Assessment, Questionnaire Administration - Glioblastoma, Malignant Glioma | Phase 1 | Active not recruiting | Sabine Mueller, MD, PhD | 9 | 2020-10-02 | 2026-06-15 |
| Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial) Ivosidenib - Recurrent Ependymoma, Recurrent Ewing Sarcoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 3 | 2020-07-20 | 2026-07-01 |
| Open-label Study Investigating of OKN-007 Combined With Temozolomide in Patients With Recurrent Glioblastoma OKN-007, Temozolomide (TMZ) - Recurrent Malignant Glioma, Brain Glioblastoma | Phase 2 | Completed | Oblato, Inc. | 57 | 2020-06-12 | 2025-08-12 |
| Chimeric Antigen Receptor (CAR) T Cells With a Chlorotoxin Tumor-Targeting Domain for the Treatment of MMP2+ Recurrent or Progressive Glioblastoma Chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes (via ICT delivery), Chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes (via ICT/ICV dual delivery) - Recurrent Glioblastoma, Recurrent Malignant Glioma | Phase 1 | Active not recruiting | City of Hope Medical Center | 19 | 2020-05-26 | 2026-10-22 |
| Fimepinostat in Treating Brain Tumors in Children and Young Adults Fimepinostat, Therapeutic Conventional Surgery - Diffuse Intrinsic Pontine Glioma, Recurrent Anaplastic Astrocytoma | Early Phase 1 | Completed | Sabine Mueller, MD, PhD | 30 | 2019-08-07 | 2026-11-02 |
| MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma Oncolytic Adenovirus Ad5-DNX-2401, Therapeutic Conventional Surgery - IDH1 wt Allele, Recurrent Anaplastic Astrocytoma | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 36 | 2019-02-12 | 2026-09-25 |
| Savolitinib in Treating Patients With Recurrent or Refractory Primary CNS Tumors Biospecimen Collection, Magnetic Resonance Imaging, Savolitinib - Recurrent Diffuse Intrinsic Pontine Glioma, Recurrent Malignant Glioma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 41 | 2018-11-27 | 2026-07-30 |
| Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial) Laboratory Biomarker Analysis, Palbociclib, Pharmacological Study - Advanced Malignant Solid Neoplasm, Recurrent Childhood Ependymoma | Phase 2 | Completed | National Cancer Institute (NCI) | 23 | 2018-08-13 | 2026-04-03 |
| STAT3 Inhibitor WP1066 in Treating Patients With Recurrent Malignant Glioma or Progressive Metastatic Melanoma in the Brain Laboratory Biomarker Analysis, Pharmacological Study, STAT3 Inhibitor WP1066 - Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma | Phase 1 | Completed | M.D. Anderson Cancer Center | 8 | 2018-07-13 | 2022-03-23 |
Showing 20 of 30. Sign in to see all of them.
Glioma (30) · Medulloblastoma (12) · Ependymoma (10) · Glioblastoma (9) · Rhabdoid Tumor (9) · Hepatoblastoma (8) · Histiocytosis, Langerhans-Cell (8) · Lymphoma, Non-Hodgkin (8) · Neuroblastoma (8) · Neuroectodermal Tumors, Primitive, Peripheral (8) · Wilms Tumor (8) · Osteosarcoma (7) · Rhabdomyosarcoma (7) · Sarcoma (7) · Central Nervous System Neoplasms (6)
Neoplasms (30) · Neoplasms by Histologic Type (30) · Neoplasms, Glandular and Epithelial (30) · Neoplasms, Nerve Tissue (30) · Neoplasms, Neuroepithelial (30) · Neuroectodermal Tumors (30) · Neoplasms, Germ Cell and Embryonal (29) · Neoplasms by Site (14) · Neuroectodermal Tumors, Primitive (11) · Nervous System Diseases (10) · Nervous System Neoplasms (10) · Neoplasms, Complex and Mixed (9) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (8) · Female Urogenital Diseases (8) · Female Urogenital Diseases and Pregnancy Complications (8)
Magnetic Resonance Spectroscopy (9) · X-Rays (7) · Specimen Handling (6) · Phantoms, Imaging (5) · Nuclear Medicine Department, Hospital (4) · Biopsy (3) · Irinotecan (2) · OKN 007 (2) · 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine (1) · Antilymphocyte Serum (1) · Bevacizumab (1) · Blood Component Removal (1) · CUDC-907 (1) · Calcium Dobesilate (1) · Chlorotoxin (1)
National Cancer Institute (NCI) (9) · City of Hope Medical Center (4) · M.D. Anderson Cancer Center (3) · Oblato, Inc. (2) · Sabine Mueller, MD, PhD (2) · Blokhin's Russian Cancer Research Center (1) · CellabMED (1) · INSYS Therapeutics Inc (1) · Jonsson Comprehensive Cancer Center (1) · Medical University Innsbruck (1) · Memorial Sloan Kettering Cancer Center (1) · Ming Yang (1) · Nationwide Children's Hospital (1) · Ohio State University Comprehensive Cancer Center (1) · University of Alabama at Birmingham (1)
United States (25) · Puerto Rico (8) · Australia (4) · Canada (2) · Austria (1) · China (1) · Russia (1) · South Korea (1) · Switzerland (1)
Behnam Badie (2) · Jana L Portnow (2) · Alice Lee (1) · Amy B Heimberger (1) · Andrea T Franson (1) · Anuradha Banerjee, MD, MPH (1) · Benjamin M Ellingson (1) · Christine A Pratilas (1) · David Khalafyan, MD (1) · David Naskhletashvili, MD, PhD (1) · Elizabeth D Alva (1) · Frederick F Lang (1) · Guenther Stockhammer, MD, Prof. (1) · James B Elder, MD (1) · James Battiste, MD, PhD (1)
PMID 31401903, PMID 28029927, PMID 34486544, PMID 34824133, PMID 37590001, PMID 38454126, PMID 39298716, PMID 40873341, PMID 42853672, PMID 42867148
U10CA180886 (8), P30CA033572 (3), UM1CA081457 (2), P50CA093459 (1), P50CA127001 (1), R01CA198076 (1), U19CA264512 (1)